Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
Demo Company

Reversing Loss of miR-122 Helps Treat Liver Cancer

By BiotechDaily International staff writers
Posted on 01 Aug 2012
A study revealed that loss of the miR-122 molecule in liver cells might cause liver cancer and that restoring the molecule might slow tumor growth.

Liver cancer is the third leading cancer killer worldwide and new treatments are greatly needed. The animal study was led by researchers at the Ohio State University (OSU) Comprehensive Cancer Center-Arthur G. James Cancer Hospital (Columbus, USA) and OSU’s Richard J. Solove Research Institute (OSUCCC-James). The scientists examined what occurs when liver cells lack a molecule called microRNA-122 (miR-122). They found that when the molecule is missing, the liver develops fat deposits, inflammation, and tumors that resemble hepatocellular carcinoma (HCC), the most common form of liver cancer.

When the researchers synthetically restored miR-122 to nearly normal levels by delivering the miR-122 gene into liver cells, it considerably reduced the size and number of tumors, with tumors making up 8% on average of liver surface area in treated animals versus 40% in control animals.

The study was published July 23, 2012, in the Journal of Clinical Investigation. “These findings reveal that miR-122 has a critical tumor-suppressor role in the healthy liver, and they highlight the possible therapeutic value of miR-122 replacement for some patients with liver cancer,” said study leader Dr. Kalpana Ghoshal, associate professor of pathology and a member of the OSUCCC-James Experimental Therapeutics Program.

MiR-122 is found principally in liver cells--it is the most plentiful microRNA in those cells--and it plays a major role in regulating cholesterol in the body. This microRNA is lost in some people with HCC, however, resulting in a poor prognosis.

For this study, Dr. Ghoshal and her colleagues developed a strain of mice that lacks miR-122 and develops HCC through the progression of events that begins with fatty liver deposits followed by inflammation and liver cancer. The researchers then used a second strain of mice that spontaneously develops liver cancer due to overexpression of a cancer-causing gene called MYC. The researchers delivered miR-122 into the animals’ livers during tumor development. Three weeks later, those treated with the molecule had smaller and fewer tumors. “The model we developed for these studies will not only facilitate our understanding of liver biology, but it will also be good for testing therapeutic efficacy of newly developed drugs against liver disease, including HCC,” Dr. Ghoshal stated.

Dr. Ghoshal also noted that research by other scientists has shown that Hepatitis C virus requires miR-122 for replication. “Because our findings demonstrate what happens when miR-122 is lost in liver cells, they might help improve the safety of new drugs that treat Hepatitis C virus infection by blocking miR-122,” she concluded.

Related Links:

Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital



Channels

Drug Discovery

view channel
Image: Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right) (Photo courtesy of Dr. Lei Wang, Baylor University College of Medicine).

Drug Candidate Propels Cancer Cells into Fatal Overdrive

A candidate drug that destroys cancer cells by stimulating them to produce more proteins than the cells can actually process was shown to kill a wide variety of cancer cells in culture and to inhibit tumor... Read more

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

Innovative Microbial Diagnostics Developer Acquired by Biomedical Giant

A biotech company noted for its development of innovative products in the field of molecular microbiology diagnostics has been acquired by one of the world's largest biomedical corporations. GeneWEAVE BioSciences, Inc.(Los Gatos, CA, USA) and Roche (Basel, Switzerland) have announced that Roche will be purchasing the... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.